Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +34.35%
#2 Siren Siren +31.73%
#3 OriginTrail OriginTrail +18.20%
#4 Purr Purr +17.28%
#5 龙虾 (Lobster) 龙虾 (Lobster) +12.28%
#6 Ethena Staked ENA Ethena Staked ENA +11.62%
#7 Wrapped XPL Wrapped XPL +11.23%
#8 DigiByte DigiByte +11.00%
#9 Collect on Fanable Collect on Fanable +10.98%
#10 Plasma Plasma +10.85%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Classement en actions #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Prix de l'action
$1.11
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$100.55M
Changement (1 jour)
-7.69%
Changement (1 an)
-7.17%
Pays
TW
Échange Senhwa Biosciences, Inc. (6492)

Catégorie

Healthcare
Le prix 6492 avec la capitalisation boursière de B
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
6492
$1.11
Capitalisation boursière de Senhwa Biosciences, Inc.(6492)
Capitalisation boursière: $100.55M
En August 2026, Senhwa Biosciences, Inc. a une capitalisation boursière de $100.55M. Cela fait de Senhwa Biosciences, Inc. la 21774th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Senhwa Biosciences, Inc. du 2014 au 2026
6492 par rapport au top 5 des plus populaires stocks
Prix pour 6492 L’actif B La capitalisation boursière de B Résultats
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$57,355.39 $100.55M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +5,182,899.16%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$50,040.67 $100.55M
Apple Inc. Apple Inc.
AAPL
$4.547T +4,521,894.34%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$45,811.46 $100.55M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +4,139,716.21%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$39,541.61 $100.55M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,573,132.23%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$30,737.65 $100.55M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,777,550.53%